BioSpace News Archive

Midatech Pharma PLC announces, further to the Company’s announcements of 13 December and 19 December 2022, that a circular and Notice of General Meeting was posted to shareholders yesterday.

Aurinia Pharmaceuticals Inc. provided an update on its business performance.

BD, a leading global medical technology company, announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023.

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine.

Aclaris Therapeutics, Inc. today is providing a corporate outlook for 2023.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) recently announced additional results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy.

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology.

Alterity Therapeutics Limited today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the “ADS Ratio”) from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the “ADS Ratio Change”).

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis, in San Francisco, CA.

Annovis Bio, Inc. today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.